Successful treatment of rare linear lichen planopilaris with Ixekizumab
Background: Lichen planopilaris (LPP) is a lymphocytic primary cicatricial alopecia characterized by perifollicular erythema, follicular hyperkeratosis and scaring, resulting in permanent hair loss. Current treatment modalities, both topical and systemic, fail to achieve satisfactory and consistent...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2023.2201364 |
| _version_ | 1797683452459352064 |
|---|---|
| author | Hanof Ahmed Mahir Petkar Martin Steinhoff |
| author_facet | Hanof Ahmed Mahir Petkar Martin Steinhoff |
| author_sort | Hanof Ahmed |
| collection | DOAJ |
| description | Background: Lichen planopilaris (LPP) is a lymphocytic primary cicatricial alopecia characterized by perifollicular erythema, follicular hyperkeratosis and scaring, resulting in permanent hair loss. Current treatment modalities, both topical and systemic, fail to achieve satisfactory and consistent results. As therapies fail to halt the inflammatory process, patients with LPP may face long-term disfigurement and significant psychological burden. Purpose: To initiate an efficacious targeted therapy with good tolerability and low side effect profile that will allow hair regrowth and prevent the development to disfiguring alopecia. Materials and methods: Here, we report on a case of rare LPP in a linear distribution (LLPP) involving the scalp and forehead failing to achieve satisfactory results with continued hair loss with multiple previous treatments. Results: Complete hair regrowth was achieved 12 weeks after treatment with an anti-psoriatic, anti-interleukin (IL)-17A/F antibody (Taltz, Ixekizumab, Lilly). Patient continued to display sustained efficacy with no reported side effects until 12 months on treatment. Conclusions: The present case underlines the viability of Ixekizumab as a possible first-line, targeted therapy for LPP and its variants with sustained efficacy. Multicenter trials are warranted to confirm the benefit of Ixekizumab as a successful targeted biologic treatment option for LPP and LLPP. |
| first_indexed | 2024-03-12T00:14:39Z |
| format | Article |
| id | doaj.art-0f92011491fc4f43bdcf1c7da6713a53 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:14:39Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-0f92011491fc4f43bdcf1c7da6713a532023-09-15T14:28:53ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532023-12-0134110.1080/09546634.2023.22013642201364Successful treatment of rare linear lichen planopilaris with IxekizumabHanof Ahmed0Mahir Petkar1Martin Steinhoff2Department of Dermatology & Venereology, Hamad Medical CorporationDepartment of Pathology, Hamad Medical CorporationDepartment of Dermatology & Venereology, Hamad Medical CorporationBackground: Lichen planopilaris (LPP) is a lymphocytic primary cicatricial alopecia characterized by perifollicular erythema, follicular hyperkeratosis and scaring, resulting in permanent hair loss. Current treatment modalities, both topical and systemic, fail to achieve satisfactory and consistent results. As therapies fail to halt the inflammatory process, patients with LPP may face long-term disfigurement and significant psychological burden. Purpose: To initiate an efficacious targeted therapy with good tolerability and low side effect profile that will allow hair regrowth and prevent the development to disfiguring alopecia. Materials and methods: Here, we report on a case of rare LPP in a linear distribution (LLPP) involving the scalp and forehead failing to achieve satisfactory results with continued hair loss with multiple previous treatments. Results: Complete hair regrowth was achieved 12 weeks after treatment with an anti-psoriatic, anti-interleukin (IL)-17A/F antibody (Taltz, Ixekizumab, Lilly). Patient continued to display sustained efficacy with no reported side effects until 12 months on treatment. Conclusions: The present case underlines the viability of Ixekizumab as a possible first-line, targeted therapy for LPP and its variants with sustained efficacy. Multicenter trials are warranted to confirm the benefit of Ixekizumab as a successful targeted biologic treatment option for LPP and LLPP.http://dx.doi.org/10.1080/09546634.2023.2201364lichen planopilariscicatricial alopeciafibrosing alopeciatargeted therapyanti-interleukin-17ixekizumab |
| spellingShingle | Hanof Ahmed Mahir Petkar Martin Steinhoff Successful treatment of rare linear lichen planopilaris with Ixekizumab Journal of Dermatological Treatment lichen planopilaris cicatricial alopecia fibrosing alopecia targeted therapy anti-interleukin-17 ixekizumab |
| title | Successful treatment of rare linear lichen planopilaris with Ixekizumab |
| title_full | Successful treatment of rare linear lichen planopilaris with Ixekizumab |
| title_fullStr | Successful treatment of rare linear lichen planopilaris with Ixekizumab |
| title_full_unstemmed | Successful treatment of rare linear lichen planopilaris with Ixekizumab |
| title_short | Successful treatment of rare linear lichen planopilaris with Ixekizumab |
| title_sort | successful treatment of rare linear lichen planopilaris with ixekizumab |
| topic | lichen planopilaris cicatricial alopecia fibrosing alopecia targeted therapy anti-interleukin-17 ixekizumab |
| url | http://dx.doi.org/10.1080/09546634.2023.2201364 |
| work_keys_str_mv | AT hanofahmed successfultreatmentofrarelinearlichenplanopilariswithixekizumab AT mahirpetkar successfultreatmentofrarelinearlichenplanopilariswithixekizumab AT martinsteinhoff successfultreatmentofrarelinearlichenplanopilariswithixekizumab |